High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - a pragmatic prognostic index
1996

High-Dose Chemotherapy and Bone Marrow Transplant for Hodgkin's Disease

Sample size: 89 publication Evidence: moderate

Author Information

Author(s): MER O'Brien, S Milan, D Cunningham, AL Jones, M Nicolson, P Selby, T Hickish, M Hill, ME Gore, C Viner

Primary Institution: The Institute of Cancer Research and The Royal Marsden Hospital

Hypothesis

Can high-dose chemotherapy with autologous bone marrow transplantation improve outcomes in patients with relapsed Hodgkin's disease?

Conclusion

High-dose chemotherapy with autologous bone marrow transplantation can lead to a significant response rate in patients with relapsed Hodgkin's disease.

Supporting Evidence

  • Of the 89 patients, 33 achieved complete remission after treatment.
  • The response rate to autologous bone marrow transplantation was 74%.
  • Patients who had never achieved a complete remission did not benefit from high-dose chemotherapy.

Takeaway

This study looked at 89 patients with Hodgkin's disease who received strong chemotherapy and a bone marrow transplant, and many of them got better.

Methodology

The study analyzed the outcomes of 89 patients treated with high-dose chemotherapy and autologous bone marrow transplantation, focusing on response rates and prognostic factors.

Potential Biases

Potential bias due to the retrospective nature of some data collection and the single-center design.

Limitations

The study was conducted at a single institution, which may limit the generalizability of the findings.

Participant Demographics

Median age of participants was 29 years, with a range from 15 to 51 years.

Statistical Information

P-Value

0.025

Confidence Interval

95% CI 60-83%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication